Following a re-examination, the European Medicines Agency’s human health committee, CHMP confirmed its initial recommendation to refuse the granting of a conditional marketing authorization for Masitinib AB Science’s masitinib. 18 October 2024
University Medical Center Groningen (UMCG) and SHINE Europe have secured a 10.5 million euro ($11 million) grant to advance European production of terbium isotopes for cancer treatments. 17 October 2024
Danish dermatology focused LEO Pharma has announced the launch of Anzupgo (delgocitinib) cream in Germany for the treatment of adult patients with moderate to severe chronic hand eczema (CHE), for whom topical corticosteroids are inadequate or inappropriate. 15 October 2024
French pharma major Sanofi revealed it has entered into negotiations with private equity firm Clayton Dubilier & Rice (CD&R) for the potential sale of a 50% controlling stake in Opella, its consumer healthcare business. 14 October 2024
The UK’s new 2024 voluntary scheme for branded medicines pricing, access, and growth (VPAG) came into force at the beginning of January this year. 4 October 2024
French drugmaker Mitem Pharmavhas the worldwide acquisition of Desferal (deferoxamine), a major MITM in hematology, from Swiss giant Novartis. 25 September 2024
The Austrian Academy of Sciences (OeAW) is further expanding its focus on life sciences by opening an institute for biomedical artificial intelligence (AI) based on a 150 million euros ($166.8 million) funding from the German non-profit Boehringer Ingelheim Foundation (BIS). 18 September 2024
Novartis is building two new radioligand therapy (RLT) manufacturing facilities in the USA to enhance its supply chain for cancer treatments. This move supports the growing use of RLTs, a form of precision medicine that targets tumors with radiation. 6 September 2024
Belgium’s largest drugmaker UCB announced a strategic divestment deal in China, underscoring its strategic shift towards innovation and partnership in one of the world’s fastest-growing pharmaceutical markets. 27 August 2024
The UK’s largest pharma company AstraZeneca has rejected claims that it is moving its vaccine operations to the USA, according to media reports. 23 August 2024
Mitsubishi Tanabe Pharma announced the termination of its exclusive sales rights agreements with AnGes for the HGF gene therapy product, Collategene (beperminogene perplasmid) intramuscular injection targeting peripheral arterial diseases in Japan and the USA. 23 August 2024
UK pharma major AstraZeneca has become the only current UK-lis¬ted company to reach a £200 billion ($256.4 billion) valuation, the Financial Times reported today, noting that it is a vindication of the company’s bet on developing a leading portfolio of cancer drugs. 14 August 2024
US pharma giant Pfizer has announced the publication of real-world results from a cohort of the longitudinal, observational Phase IV THAOS (Transthyretin Amyloidosis Outcomes Survey) study in the Journal of Cardiac Failure. 8 August 2024
Japanese drugmaker Shionogi says that its New Drug Application (NDA) for cefiderocol has been accepted for review by the Center for Drug Evaluation, National Medical Products Administration (NMPA). 5 August 2024
Germany’s Bayer has submitted to the US Food and Drug Administration for approval to market elinzanetant for moderate to severe vasomotor symptoms (VMS), commonly known as hot flashes, associated with menopause. 2 August 2024
Spanish plasma-derived medicines company Grifols announced with the Andorran government the cancellation of the immunology research center planned for the parish of Ordino. 29 July 2024
The US Food and Drug Administration (FDA) approved Palforzia (peanut [Arachis hypogaea] allergen powder-dnfp] to include initiation of treatment, up-dosing and maintenance in individuals ages one through three years. 27 July 2024
Vividion Therapeutics, a wholly-owned subsidiary of Germany’s Bayer, today announced it will expand its global innovation capabilities with a new research and development (R&D) center and corporate headquarters in San Diego, California. 23 July 2024
US pharm major Eli Lilly on Friday revealed via a social media posting that it has been granted approval from the Chinese National Medical Products Administration (NMPA) to sell tirzepatide for weight loss in the country. 20 July 2024
The US Food and Drug Administration (FDA) issued a draft guidance for industry, “Pediatric Inflammatory Bowel Disease: Developing Drugs for Treatment,” to help sponsors in the clinical development of drugs to treat pediatric patients with inflammatory bowel disease (IBD). 19 July 2024
International aid group Médecins Sans Frontières (MSF) has welcomed new guidance from the World Health Organization (WHO) in relation to cryptococcal disease, while raising concerns over the accessibility of relevant treatments. 8 March 2018
Shares in Express Scripts, the USA’s largest pharmacy benefit manager (PBM), were up by 12% in mid-morning trading on Thursday after news emerged that it was to be taken over in a $67 billion deal. 8 March 2018
Shares in Darmstadt-based Merck KGaA slumped almost 5% by mid-afternoon today, as the German chemicals and pharmaceuticals manufacturer revealed a drop in earnings due to a “difficult foreign exchange environment,” and Chinese competition in its liquid crystals business. 8 March 2018
Indian drugmaker Zydus Cadila has partnered with Canadian cardiovascular drug discovery and development firm Medicure to commercialize Zypitamag (pitavastatin magnesium). 8 March 2018
Despite releasing encouraging new data on its cholesterol lowerer, US lipid management firm Esperion Therapeutics saw its shares plunged as much as 10.2% before paring some of those losses and finishing at $76.29, down 2.1% yesterday. 8 March 2018
Days after the Prime Minister Theresa May brought some cheer to Brexit-fearing pharma companies with a presence in the UK by saying that her government favored remaining part of the European Medicines Agency (EMA) after formally leaving the European Union (EU), that hope has been dented by the EU. 7 March 2018
Given how busy mergers and acquisitions (M&A) activity was across pharma and biotech in January, it was perhaps not surprising that February was a quieter month, but three of pharma's biggest players still dipped their hands in their pockets. 7 March 2018
Active deal-maker Ligand Pharmaceuticals has granted Roivant Sciences exclusive global rights to develop and commercialize LGD-6972, Ligand’s glucagon receptor antagonist (GRA), under development for the treatment of type 1 and 2 diabetes. 7 March 2018
East Coast-based Sunovion Pharmaceuticals, a wholly-owned subsidiary of Japan’s Sumitomo Dainippon Pharma has successfully expanded the use of Latuda (lurasidone) in the USA. 7 March 2018
Privately-held Swiss drugmaker Ferring Pharmaceuticals has teamed up with March of Dimes to open the US nonprofit’s first research center in Europe. 7 March 2018
USA-based UnitedHealthcare, a UnitedHealth Group (NYSE: UNH) company, announced on Tuesday that it will expand pharmacy discounts to millions of its plan participants when they fill prescriptions through retail pharmacies or home delivery. 7 March 2018
Japanese drugmaker Eisai and co-developer Purdue Pharma have announced positive topline results related to investigational therapy lemborexant, currently being studied for the treatment of multiple sleep disorders. 7 March 2018
On Friday, the UK Prime Minister Theresa May finally provided some clarity on what she wants the UK’s future relationship with the European Medicines Agency (EMA) to look like as part of her “Road to Brexit” speech. 6 March 2018
A review published in JAMA Oncology has shown the overall success of the US Food and Drug Administration’s (FDA) accelerated approval (AA) program for getting promising cancer drugs to patients faster. 6 March 2018
A new collaboration between pharmaceutical companies and non-profit organizations will manufacture and supply a new, more affordable, hepatitis C treatment regimen in Latin America. 6 March 2018
Xolair (omalizumab) came out unfavorably in a comparison with a new competitor in severe eosinophilic asthma in trial results presented on Monday, but news on Tuesday showed the Novartis (NOVN: VX) drug up in a more positive light. 6 March 2018
Russia can tighten a control on foreign medical laboratories and pharmaceutical companies, operating in the domestic market, according to the press-service of the Russian government and sources in the country’s special services. 6 March 2018
UK drug major GlaxoSmithKline has presented results showing a positive impact of switching to its asthma drug Nucala (mepolizumab) when patients are uncontrolled despite receiving Xolair (omalizumab), a rival therapy marketed by Swiss pharma giant Novartis. 5 March 2018